Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

ABSTRACT:

Introduction

Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.

Methods

We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau₁₈₁ and t-tau) and ¹⁸F-PI-2620 tau-positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).

Results

Elevated CSF p-tau₁₈₁ and cortical ¹⁸F-PI-2620 binding was characteristic for AD while normal CSF p-tau₁₈₁

SUBMITTER: Dilcher R 

PROVIDER: S-EPMC11485081 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature